Home LiteratureArticle Details
PMID: 3179930 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer.

Cancer ·Vol. 62 ·No. 10 ·1988-11-15 ·Pages 2183-90

Kallioniemi OP, Blanco G, Alavaikko M, Hietanen T, Mattila J, Lauslahti K, Lehtinen M, Koivula T

Abstract

To optimize the prognostic value of DNA flow cytometry in breast cancer the authors calculated several parameters from the DNA histogram, including the DNA index, the size and number of aneuploid peaks as well as S-phase and G2/M-phase cell cycle fractions. Of these, DNA index and S-phase fraction (SPF) proved to be the most valuable prognostic indices. DNA aneuploidy was associated with a three-fold risk of death as compared to DNA diploidy (P less than 0.0001). The highest risk of death was associated with hypertetraploid (greater than 2.20) DNA index, whereas a tetraploid DNA index (1.80-2.20) was associated with a relatively low risk. The SPF had significant additional prognostic value in both DNA diploid (P = 0.0002) and DNA aneuploid (P = 0.02) tumors. By combining DNA index and SPF the authors defined three types of DNA histograms, which were associated with favorable, intermediate, and poor prognosis of the patients. DNA diploidy together with low (less than 7%) SPF (type I DNA histogram) was associated with very favorable prognosis, whereas DNA aneuploidy with high DNA index (greater than 2.20) or high (greater than 12%) SPF (type III DNA histogram) was related to the worst prognosis with approximately eight-fold relative risk of death. In a Cox multivariate regression analysis the type of DNA histogram was an independent and most powerful prognostic indicator in breast cancer. The other independent factors in the Cox analysis were primary tumor size, nodal status, and progesterone receptor status.

MeSH Terms
Aged Antineoplastic Combined Chemotherapy Protocols/therapeutic use Breast Neoplasms/classification,drug therapy,pathology,surgery Cyclophosphamide/administration & dosage DNA, Neoplasm/analysis Female Flow Cytometry/methods Fluorouracil/administration & dosage Follow-Up Studies Humans Interphase Mastectomy Menopause Methotrexate/administration & dosage Middle Aged Neoplasm Staging Prognosis Receptors, Estrogen/analysis Receptors, Progesterone/analysis
Chemicals
DNA, Neoplasm Receptors, Estrogen Receptors, Progesterone Cyclophosphamide Fluorouracil Methotrexate
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Kallioniemi O P
Department of Clinical Chemistry, Tampere University Central Hospital, Finland.
Blanco G
Alavaikko M
Hietanen T
Mattila J
Lauslahti K
Lehtinen M
Koivula T
Supplementary Concepts
CMF regimen (Protocol)
Article Info
Journal
Cancer
Abbr.
Cancer
ISSN
0008-543X
Published
1988-11-15
Pages
2183-90
Language
English
Region
United States
NLM ID
0374236
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]